Creative Medical launches a veterans initiative to address toxic burn pit exposure using advanced regenerative and AI technologies.
Quiver AI Summary
Creative Medical Technology Holdings, Inc. has launched the BioDefense Inc. Veterans Initiative, a groundbreaking national program aimed at addressing the long-term health effects of toxic burn pit exposure among U.S. veterans. This initiative marks a significant step in enhancing America's biodefense capabilities and integrating regenerative medicine into veteran health security. Utilizing proprietary technologies and AI analytics, the program will create an extensive molecular database to inform precision treatments for damage caused by toxic exposure. The initiative is led by BioDefense Inc., supported by a partnership with Greenstone Biosciences, which will provide advanced AI and molecular analysis. Together, they aim to redefine veteran healthcare by developing predictive models and regenerative therapies, thus establishing a new national pillar for health security that merges biotechnology and patriotism.
Potential Positives
- The launch of the BioDefense Inc. Veterans Initiative positions Creative Medical as a leader in addressing the health impacts of toxic burn pit exposure on veterans, demonstrating a commitment to veteran health security.
- Creative Medical's collaboration with Greenstone Biosciences to utilize AI and advanced molecular technologies enhances their ability to develop precision regenerative therapies, which could significantly advance the field of biodefense medicine.
- The initiative aims to create one of the largest molecular-level databases of veteran toxic exposure, which may provide critical insights for future medical interventions and disease modeling.
- This program establishes a framework for integrating biotechnology and artificial intelligence into national health security strategies, potentially attracting attention and investment in the biotech sector.
Potential Negatives
- The press release contains numerous forward-looking statements about the program's expected results and benefits, which introduces significant uncertainty regarding its actual implementation and efficacy.
- There is a reliance on a partnership with Greenstone Biosciences for critical technological aspects, which could pose risks if that partnership does not meet expectations.
- The ambitious scope of the BioDefense initiative raises questions about the company's capacity to execute such a large-scale program effectively, potentially leading to public skepticism.
FAQ
What is the BioDefense Inc. Veterans Initiative?
The BioDefense Inc. Veterans Initiative aims to address health issues related to toxic burn pits among U.S. service members using advanced technologies.
How does Creative Medical plan to utilize AI in the initiative?
Creative Medical will use AI-powered analytics to model and reverse disease pathways related to toxic exposure among veterans.
What partnership supports the BioDefense Inc. program?
Creative Medical has partnered with Greenstone Biosciences to leverage AI and iPSC technology for analyzing cellular data from exposed service members.
How will the initiative impact veteran healthcare?
It will create predictive models and precision therapies, transforming the diagnosis and treatment of diseases caused by toxic exposure in veterans.
What is the goal of the Burn Pit Exposure Molecular Characterization Program?
The goal is to develop a comprehensive database on toxic exposure to improve diagnosis and regenerative treatments for veterans.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CELZ Hedge Fund Activity
We have seen 6 institutional investors add shares of $CELZ stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 148,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $392,200
- HRT FINANCIAL LP removed 13,053 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $34,590
- NORTHERN TRUST CORP added 11,707 shares (+inf%) to their portfolio in Q2 2025, for an estimated $31,023
- CITADEL ADVISORS LLC added 11,145 shares (+inf%) to their portfolio in Q2 2025, for an estimated $29,534
- ALLWORTH FINANCIAL LP added 4,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $10,600
- GEODE CAPITAL MANAGEMENT, LLC added 2,608 shares (+14.3%) to their portfolio in Q2 2025, for an estimated $6,911
- AMERITAS ADVISORY SERVICES, LLC added 2,276 shares (+inf%) to their portfolio in Q2 2025, for an estimated $6,031
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
PHOENIX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage leader in regenerative and cellular innovation, today announced the official launch of its BioDefense Inc. Veterans Initiative , believed to be a first-of-its-kind national program to combat the devastating long-term effects of toxic burn pit exposure among U.S. service members.
This initiative underscores the Company’s commitment to establishing a mission-critical role in America’s biodefense infrastructure by positioning Creative Medical as a cornerstone of national medical readiness and veteran health security. The program will utilize Creative Medical’s proprietary iPSC and regenerative repair technologies and algorithms, coupled with AI-powered analytics, to identify, model, and reverse toxic-exposure-related disease pathways.
Uniting Science, Service, and Sovereignty
BioDefense Inc., a subsidiary of Creative Medical, is spearheading the Burn Pit Exposure Molecular Characterization Program, designed to create one of the largest molecular-level databases of veteran toxic exposure in U.S. history. This platform will serve as the foundation for precision regenerative countermeasures, transforming the way respiratory, cardiovascular, and neurological damage from toxic exposure is diagnosed and treated.
“This is not just a scientific program, it’s a national imperative,” said Timothy Warbington, President and CEO of Creative Medical. “Our veterans gave everything for this country. Through BioDefense Inc., we’re giving them something back: cutting-edge regenerative technology born from American innovation, powered by AI, and built to secure the health of those who secured our freedom.”
Partnership with Greenstone Biosciences: Powering the AI Revolution in Regenerative Biodefense
To execute this disruptive initiative, Greenstone Biosciences, Inc., a Palo Alto–based biotechnology leader founded by Dr. Joseph C. Wu of Stanford University and recently partnered with
NVIDIA
1,2
, has been selected as the exclusive AI and iPSC development partner.
Under this partnership, Greenstone will deploy advanced molecular-sequencing, proteomic profiling, and machine-learning algorithms to analyze cellular data from service members exposed to burn pits. These AI-integrated systems will accelerate the creation of predictive exposure models and precision-engineered regenerative therapies—a groundbreaking leap in both biodefense and AI-enabled medicine.
“Greenstone’s machine learning and iPSC expertise will serve as the computational engine behind our national regenerative defense platform,” added Warbington. “Together, we’re not only redefining veteran healthcare, we’re building a scalable system that can respond to any biological threat, military or civilian.”
BioDefense Inc.: Establishing a New National Capability
BioDefense Inc. is executing a national program which will provide the critical data infrastructure to:
• Decode the genomic and proteomic architecture of toxic-exposure-related injury.
• Engineer iPSC-based regenerative repair models using Creative Medical’s patented cell platform.
• Validate next-generation AI/ML biodefense algorithms for exposure classification and precision intervention.
• Develop predictive, preemptive disease modeling systems for deployment across military and civilian populations.
Through this initiative, Creative Medical is establishing AI-integrated regenerative biodefense as a new national pillar of health security—uniting biotechnology, artificial intelligence, and patriotism into one transformative mission.
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a clinical-stage biotechnology company driving innovation across regenerative medicine, immune modulation, and induced pluripotent stem cell (iPSC) technology. Its platform powers programs in autoimmune, inflammatory, neurological, metabolic, and biodefense medicine, integrating cellular regeneration and AI-enabled analytics to fortify national medical resilience. For more information, visit
www.creativemedicaltechnology.com
or
www.biodefenseinc.com
About Greenstone Biosciences, Inc.
Greenstone Biosciences is a Palo Alto–based computational biotechnology company advancing AI-integrated drug discovery and iPSC modeling. Cofounded by Dr. Joseph C. Wu, Professor of Medicine and Radiology at Stanford University and Jade Chao, JD, MPH, Greenstone fuses automation, high-throughput biology, and computational modeling to accelerate the discovery of next-generation precision therapies. For more information, visit
www.greenstonebio.com
.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, among others, statements regarding expected results, potential benefits, and development timelines of the BioDefense Inc. burn pit exposure program and related collaborations. Actual results may differ materially due to various risks and uncertainties, including those detailed in Creative Medical Technology Holdings’ filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update these statements except as required by law.
2 NVIDIA GTC Washington, DC: Live Updates on What’s Next in AI | NVIDIA Blog : NVIDIA Clara Open Models Jumpstart Scientific and Medical Collaboration at Scale
Contact:
Creative Medical Technology Holdings, Inc.
Investor Relations:
[email protected]
Devin Sullivan, Managing Director – The Equity Group Inc.
[email protected]
Conor Rodriguez, Associate – The Equity Group Inc.
[email protected]
Dave Gentry – RedChip Companies
1-800-REDCHIP (733-2447)
[email protected]
Greenstone Biosciences, Inc.
Investor Relations: [email protected]
Jade Chao, JD, General Counsel
[email protected]
(650) 714-7060
